Stroke is a disease of ageing affecting millions of people worldwide, and recombinant tissue-type plasminogen activator (r-tPA) the only treatment approved. However, r-tPA has a low therapeutic window and secondary effects which limit its beneficial outcome, urging thus the search for new more efficient therapies. Among them, neuroprotection based on melatonin or nitrones, as free radical traps, have arisen as drug candidates due to their strong antioxidant power. In this Perspective, an update on the specific results of the melatonin and several new nitrones are presented.
No takes yet. Share an insight, caveat, or question.
Romero et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: